BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Quemliclustat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Quemliclustat\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06048133-2695@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Quemliclustat: Phase 2 readout est. (NCT06048133)
DESCRIPTION:Quemliclustat\, phase 2.\nStudy: Study of Gemcitabine\, Cisplat
 in\, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract
  Cancers (QUIC)\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/quemliclustat#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06048133
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05915442-2695@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Quemliclustat: Phase 2 readout est. (NCT05915442)
DESCRIPTION:Quemliclustat\, phase 2.\nStudy: Adenosine Signaling Modulation
  and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic P
 rostate Cancer\nEstimated primary completion: 1 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/quemliclustat#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05915442
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06048484-2695@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Quemliclustat: Phase 2 readout est. (NCT06048484)
DESCRIPTION:Quemliclustat\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: Combination Therapy in Patients With Localized Pancreatic Ductal Aden
 ocarcinoma\nEstimated primary completion: April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/quemliclustat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06048484
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05676931-2695@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quemliclustat: Phase 2 readout est. (NCT05676931)
DESCRIPTION:Quemliclustat\, phase 2.\nStudy: Study With Various Immunothera
 py Treatments in Participants With Lung Cancer\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qu
 emliclustat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05676931
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05688215-2695@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Quemliclustat: Phase 1/2 readout est. (NCT05688215)
DESCRIPTION:Quemliclustat\, phase 1/2\, Pancreatic Ductal Adenocarcinoma.\n
 Study: Zimberelimab and Quemliclustat in Combination With Chemotherapy for
  the Treatment of Patients With Borderline Resectable and Locally Advanced
  Pancreatic Adenocarcinoma\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/quemliclustat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05688215
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667335-2695@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Quemliclustat: Phase 1/2 readout est. (NCT07667335)
DESCRIPTION:Quemliclustat\, phase 1/2.\nStudy: Enfortumab Vedotin\, Pembrol
 izumab and Quemliclustat for the Treatment of Unresectable Locally Advance
 d and Metastatic Urothelial Cancer\nEstimated primary completion: 16 July 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/quemliclustat#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07667
 335
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06608927-2695@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Quemliclustat: Phase 3 readout est. (NCT06608927)
DESCRIPTION:Quemliclustat\, phase 3\, Pancreatic Ductal Adenocarcinoma.\nSt
 udy: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemothera
 py in Patients With Metastatic Pancreatic Ductal Adenocarcinoma\nEstimated
  primary completion: 30 November 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/quemliclustat#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06608927
URL:https://assetmemo.bio/drug/quemliclustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
